MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566

Contributing Authors: AJ Chou ES Kleinerman MD Krailo Z Chen DL Betcher JH Healey Conrad EU ML Nieder MA Weiner RJ Wells RB Womer PA Meyers Children's Oncology Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Explore some of our unlocked reports below!

Treatment of osteoarthritis: A role for education programmes?

The prevalence of intimate partner violence in women presenting to orthopaedic clinics

Osteoporosis Choice decision aid improves treatment experience of clinicians and patients

Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.

MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients

To view the full report, start your 30-day free trial today

Explore some of our unlocked reports below!

Continuing Medical Education Credits

Please be patient while we setup your OrthoEvidence account.

Please be patient
while we setup your
OrthoEvidence account.